



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/160,076 09/24/98 SCOTT

D 308072000110

EXAMINER
----------

HM22/0116

SHMUEL LIVNAT  
MORRISON & FOERSTER  
2000 PENNSYLVANIA AVENUE NW  
WASHINGTON DC 20006-1888

WILSON, M	
ART UNIT	PAPER NUMBER

1633  
DATE MAILED:


20

01/16/01

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trad marks**

File copy

<b>Interview Summary</b>	Application No. <b>09/160,076</b>	Applicant(s) <b>Scott et al.</b>	
	Examiner <b>Wilson, Michael C.</b>	Group Art Unit <b>1633</b>	

All participants (applicant, applicant's representative, PTO personnel):

- (1) Wilson, Michael C. (3) \_\_\_\_\_  
 (2) Catherine Kara (4) \_\_\_\_\_

Date of Interview Jan 9, 2001

Type: ☒ Telephonic ☐ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☒ Yes ☐ No. If yes, brief description:

Proposed claimed faxed by Ms. Kara.

Agreement ☐ was reached. ☒ was not reached.

Claim(s) discussed: proposed claims in general

Identification of prior art discussed:

Zambidis

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:

The general nature of the invention was discussed regarding the antigens that could be fused with IgG in the vector claimed and the immune response obtained. Enablement and written discription issues regarding the antigens and the degree of "tolerance" supported by the specification taken with the knowledge in the prior art at the time of filing were discussed. Claim language that specifically describes the antigens encoded by the vector that is tolerogenic and differs from the lambda protein of Zambidis is suggested. The correlation between autoimmune, allergen proteins and other proteins (lambda and albumin) was discussed as they relate to the type of immune response that each type of protein causes. Applicants representative will file a declaration with additional evidence to support vectors encoding other fusion proteins.


(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☒ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign and stamp this form unless it is an attachment to a signed Office action.

  
 AU 1633